![\"Rodney](\"https:\/\/www.iths.org\/course-instructors\/wp-content\/uploads\/sites\/31\/2019\/02\/ho.jpg\")
<\/p>\n<\/p>\n
Professor,\u00a0 Pharmaceutics, Bioengineering (Adjunct) Dr. Ho is a professor of Pharmaceutics and UW Presidential Entrepreneurial Fellow. He holds appointments at the Institute of Translational Health Sciences, Center on Human Development & Disability and Fred Hutchinson Cancer Research Center. His research involves drug targeting and translational medicine.<\/p>\n He is noted for linking drug levels at target sites in the body to disease symptoms. He is an expert on translation of proteins into Biotherapeutics. Building on the knowledge of target cells and tissues pivotal to disease progressions, he develops nanomedicine and device-enabled technologies that make anti-infective agents such as HIV, pain and cancer medications more effective and safe.<\/p>\n He completed an Infectious Diseases Fellowship at Stanford University. Dr. Ho has been elected to Fellow status at the American Association for the Advancement of Science and the American Association of Pharmaceutical Scientists.<\/p>\n He has received some of his field\u2019s highest honors, including the American Association of Colleges of Pharmacy\u2019s Dawson Biotechnology Award and the AAPS Biotechnology Lifetime Achievement Award.<\/p>\n He has received continuous major research funding from the National Institutes of Health (NIH) that has led to over 100 publications related to improving drug delivery, transport, metabolism, safety and effectiveness.<\/p>\n","protected":false},"excerpt":{"rendered":" Rodney Ho, PhD, FAAAS, FAAPS Professor,\u00a0 Pharmaceutics, Bioengineering (Adjunct) Director of the Targeted Long-Acting Combination Antiretroviral Therapy (TLC- ART) Program University of Washington Affiliate Member of Clinical Pharmacology, Fred Hutchinson Cancer Research Center Affiliate Faculty, UW Center for AIDS Research Dr. Ho is a professor…<\/p>\n","protected":false},"author":2,"featured_media":116,"parent":97,"menu_order":1700,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_custom_body_class":"","_custom_post_class":"","footnotes":""},"class_list":["post-36","page","type-page","status-publish","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/www.iths.org\/cc\/wp-json\/wp\/v2\/pages\/36","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.iths.org\/cc\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.iths.org\/cc\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.iths.org\/cc\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.iths.org\/cc\/wp-json\/wp\/v2\/comments?post=36"}],"version-history":[{"count":7,"href":"https:\/\/www.iths.org\/cc\/wp-json\/wp\/v2\/pages\/36\/revisions"}],"predecessor-version":[{"id":919,"href":"https:\/\/www.iths.org\/cc\/wp-json\/wp\/v2\/pages\/36\/revisions\/919"}],"up":[{"embeddable":true,"href":"https:\/\/www.iths.org\/cc\/wp-json\/wp\/v2\/pages\/97"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.iths.org\/cc\/wp-json\/wp\/v2\/media\/116"}],"wp:attachment":[{"href":"https:\/\/www.iths.org\/cc\/wp-json\/wp\/v2\/media?parent=36"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nDirector of the Targeted Long-Acting Combination Antiretroviral Therapy (TLC- ART) Program<\/em>
\nUniversity of Washington
\nAffiliate Member of Clinical Pharmacology, <\/em>Fred Hutchinson Cancer Research Center
\nAffiliate Faculty<\/em>, UW Center for AIDS Research<\/p>\n